- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04740476
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001
Study Overview
Detailed Description
This study is a multi-center, open-label, multiple-dose, safety extension study for patients who have completed another study of STK-001 and meet study eligibility criteria. STK-001 is an investigational new medicine for the treatment of Dravet syndrome. STK-001 is an antisense oligonucleotide (ASO) that is intended to increase the level of productive SCN1A messenger RNA (mRNA) and consequently increase the expression of the sodium channel Nav1.1 protein. This RNA-based approach is not gene therapy, but rather RNA modulation, as it does not manipulate nor insert genetic deoxyribonucleic acid (DNA).
STK-001 is designed to upregulate Nav1.1 protein expression from the nonmutant (wild-type) copy of the SCN1A gene to restore physiological Nav1.1 levels. Nav1.1 levels are reduced in people with Dravet syndrome. Stoke has generated preclinical data demonstrating proof-of-mechanism for STK-001.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94158
- University of California San Francisco Medical Center
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Children's Hospital Colorado
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Medical Center
-
-
Florida
-
Miami, Florida, United States, 33155
- Nicklaus Children's Hospital
-
Orlando, Florida, United States, 32803
- Florida Hospital for Children
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Children's Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Michigan Medicine
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10016
- NYU Comprehensive Epilepsy Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Tennessee
-
Memphis, Tennessee, United States, 38103
- UT LeBonheur Pediatric Specialists, Inc.
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Cook Children's Medical Center
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
Tacoma, Washington, United States, 98405
- MultiCare Health System Institute for Research and Innovation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Completed dosing with STK-001 and the End of Study Visit in Study STK-001-DS-101, with an acceptable safety profile per Investigator judgment.
- Had satisfactory compliance with study visits and procedures in Study STK-001-DS-101 per Investigator and Sponsor judgment.
- Completed Study STK-001-DS-101 within 4 weeks of the start of their participation in Study STK-001-DS-501 unless approved by sponsor.
Exclusion Criteria:
- Met any withdrawal criteria from Study STK-001-DS-101.
- Currently treated with an antiepileptic drug (AED) acting primarily as a sodium channel blocker, as maintenance therapy, including phenytoin, carbamazepine, oxcarbazepine, lamotrigine, lacosamide, or rufinamide.
- Clinically significant unstable medical conditions other than epilepsy.
- Clinically relevant symptoms or a clinically significant illness (in the judgment of the Investigator) at Screening or prior to dosing on Day 1, other than epilepsy.
- Spinal deformity or other condition that may alter the free flow of CSF or has an implanted CSF drainage shunt.
- Treated (or is being treated) with an investigational product (other than STK-001) since participating in Study STK-001-DS-101.
- Participating in an observational study, they are excluded unless approved by the Sponsor.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: STK-001 multiple dose levels
Enrollment of patients after completion of study STK-001-DS-101 if eligible for additional dosing in this extension study.
Patients will receive IT administration of study drug STK-001 at the dose level they received while participating in Study STK-001-DS-101, or at a dose level recommended by the Safety Monitoring Committee (SMC).The highest dose administered in this study may not exceed that which has already been evaluated in an STK-001 Phase 1/2 study, and doses above 30 mg/dose in this study require approval from the Food and Drug Administration (FDA).
Patients will initially receive 3 doses, one every approximately 4 months (16 weeks).
Patients who are tolerating treatment may continue treatment with doses approximately every 4 months, with an End of Study/Follow-up Visit 24 weeks after the last dose of study drug.
Patients who do not continue treatment after the third dose will have a Follow-up Visit (V5) at Week 48 and an End of Study Visit at Week 56.
|
STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of multiple doses of STK-001
Time Frame: Screening (Day -1) until 6 months after multiple drug dosing
|
Safety variables for analysis include the incidence, type, severity, and seriousness of AEs, and changes in vital signs, ECG, laboratory, immunogenicity, physical examination, and Gillette FAQ parameters.
|
Screening (Day -1) until 6 months after multiple drug dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic (PK) Parameters
Time Frame: Dosing (Day 1) until 6 months after multiple drug dosing
|
Analysis of plasma concentrations of STK-001
|
Dosing (Day 1) until 6 months after multiple drug dosing
|
Exposure of STK-001 in Cerebrospinal Fluid (CSF)
Time Frame: Dosing (Day 1) until Week 32 (last study drug dosing day)
|
Measurement of STK-001 concentrations
|
Dosing (Day 1) until Week 32 (last study drug dosing day)
|
Measurement of Seizure Frequency
Time Frame: Screening (Day -1) until 6 months after multiple drug dosing
|
Measurement of Seizure Frequency (by paper diary)
|
Screening (Day -1) until 6 months after multiple drug dosing
|
Change in overall clinical status
Time Frame: Screening (Day -1) until 6 months after multiple drug dosing
|
Change in overall clinical status as measured by the Clinical Global Impression of Change (CGIC) and the Caregiver Global Impression of Change (CaGIC)
|
Screening (Day -1) until 6 months after multiple drug dosing
|
Change in Quality of Life
Time Frame: Screening (Day -1) until 6 months after multiple drug dosing
|
Change in quality of life as measured by the EuroQoL-five dimensions, youth version (EQ-5D-Y) instrument
|
Screening (Day -1) until 6 months after multiple drug dosing
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ann Dandurand, MD, Medical Director
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STK-001-DS-501
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dravet Syndrome
-
University Health Network, TorontoZogenix, Inc.Not yet recruiting
-
TakedaActive, not recruitingDravet Syndrome (DS)China, United States, Canada, France, Hungary, Australia, Poland, Spain, Japan, Belgium, Greece, Brazil, Serbia, Germany, Italy, Latvia, Netherlands, Russian Federation, Ukraine
-
TakedaRecruitingLennox Gastaut Syndrome (LGS) | Dravet Syndrome (DS)United States, China, Spain, France, Belgium, Australia, Brazil, Canada, Germany, Greece, Hungary, Italy, Japan, Latvia, Netherlands, Poland, Serbia, Mexico, Russian Federation, Ukraine
-
TakedaRecruitingDravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)Spain
-
TakedaActive, not recruitingEpilepsy | Dravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)United States, Canada, Australia, China, Israel, Poland, Spain, Portugal
-
Encoded TherapeuticsNot yet recruiting
-
Boston Children's HospitalEncoded TherapeuticsRecruitingDravet SyndromeUnited States
-
Stoke Therapeutics, IncActive, not recruiting
-
Zogenix International Limited, Inc., a subsidiary...CompletedDravet SyndromeUnited States, United Kingdom, Spain, Belgium, Italy, Australia, Denmark, Germany, Canada, Japan, Netherlands, France
-
Gillette Children's Specialty HealthcareMayo Clinic; Dartmouth-Hitchcock Medical Center; Ann & Robert H Lurie Children...CompletedDravet SyndromeUnited States
Clinical Trials on STK-001
-
Stoke Therapeutics, IncActive, not recruiting
-
SynthekineRecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | NHL | CLL/SLL | Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
Toll Biotech Co. Ltd. (Beijing)Recruiting
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States
-
IntegoGen, LLCWithdrawnHidradenitis SuppurativaUnited States
-
JANSSEN Alzheimer Immunotherapy Research & Development...TerminatedAlzheimer's DiseaseUnited States
-
Heartseed Inc.RecruitingHeart Failure | Ischemic Heart DiseaseJapan
-
Frontera TherapeuticsRecruitingBiallelic RPE65 Mutation-associated Retinal DystrophyChina
-
Azura OphthalmicsSyneos Health; Cliantha ResearchCompletedDry Eye | Meibomian Gland DysfunctionCanada, Australia, New Zealand
-
Longbio PharmaActive, not recruitingMyelodysplastic Syndrome (MDS)China